Appointment enhances strategic and financial leadership as the Company advances CMP-002 toward a planned first-in-human Phase 1/2 clinical trial for SYNGAP1-related disorderCAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad ...

Summary of Camp4 Therapeutics Conference Call Company Overview - **Company**: Camp4 Therapeutics (NasdaqGM:CAMP) - **Event**: Global Healthcare Conference of Leerink Partners, March 09, 2026 Technology Platform - **Core Technology**: Utilizes antisense oligonucleotides (ASOs) to increase gene expression, targeting regulatory RNAs from the non-coding genome, specifically enhancers and promoters [4][5] - **Differentiation**: Unlike traditional oligonucleotide therapies that focus on downregulation, Camp4's approach allows for precise upregulation of gene expression, particularly in haploinsufficient conditions [4][5][10] - **Targeting Mechanism**: The platform catalogs regulatory RNAs and their corresponding genes in various cell types, enabling targeted drug development [4] Clinical Focus - **Haploinsufficient Diseases**: The company focuses on diseases where patients are missing 50% of necessary gene expression, aiming for a twofold increase in expression as the ideal target [10][11] - **Current Programs**: Shifted focus from urea cycle disorder (UCD) to the SYNGAP1 program due to higher conviction in clinical success and significant unmet medical need [19][21] - **SYNGAP1 Disease**: A haploinsufficient condition with no approved treatments, characterized by cognitive impairment, seizures, and mobility issues [27][28] Clinical Development Strategy - **Target Population**: Aiming to treat children diagnosed with SYNGAP1 as early as age 2 or 3, leveraging advancements in genetic testing for quicker diagnosis [39][41] - **Dosing Strategy**: Plans to initiate with multiple ascending dose (MAD) studies directly, based on regulatory feedback and the high unmet need of the patient population [49][50] - **Endpoints**: Focus on various clinical endpoints including seizure frequency, cognitive assessments, and overall quality of life metrics [61][63] Preclinical Data - **Efficacy**: Demonstrated ability to reverse disease symptoms in preclinical models, including humanized mice and primates, with a consistent twofold increase in protein expression [64][66] - **Safety**: No safety issues reported in preclinical studies, reinforcing confidence in the therapeutic approach [22][66] Collaboration and Future Opportunities - **GSK Collaboration**: Engaged in a partnership with GSK to explore additional therapeutic indications, with a focus on CNS and kidney diseases [85][87] - **Pipeline Expansion**: Plans to develop additional programs targeting similar haploinsufficient conditions, with potential for significant market opportunities [90][91] Key Takeaways - **Market Potential**: The SYNGAP1 program is viewed as a multi-billion dollar opportunity, with the potential to unlock further value for the platform as additional programs are developed [94] - **Regulatory Engagement**: Ongoing discussions with regulatory agencies are positive, indicating familiarity and comfort with the technology, which may expedite clinical development [82][83] This summary encapsulates the key points discussed during the conference call, highlighting the innovative approach of Camp4 Therapeutics in addressing significant unmet medical needs through their unique technology platform and strategic clinical focus.

GLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026 Entered strategic collaboration with GSK to advance RNA-based therapeutic discoveries, received $17.5 million upfront and eligible for milestone-based payments in addition to tiered royalties Completed private placement with upfront gross proceeds of $50 million, with potential for up to an additional $50 million of gross proceeds, as well as underwritten offering ...

Company Overview - CAMP4 is focused on using antisense oligonucleotides to selectively increase gene expression, positioning itself as a product company with a powerful platform [3]. Key Program - The flagship program of CAMP4 targets SYNGAP1-related disorders, a genetic haploinsufficiency CNS disorder with no approved treatments or disease-modifying therapies currently in development [4]. - The lead program for SYNGAP is CMP-002, which aims to be the first to enter clinical trials with a disease-modifying approach [4]. Market Potential - There are tens of thousands of patients suffering from SYNGAP around the world, indicating a significant unmet medical need [4].

Camp4 Therapeutics FY Conference Summary Company Overview - **Company**: Camp4 Therapeutics (NasdaqGM:CAMP) - **Industry**: Biotechnology, focusing on genetic disorders and CNS diseases - **Key Product**: CMP-002, an antisense oligonucleotide targeting SYNGAP1-related disorders Core Insights and Arguments 1. **Flagship Program**: Camp4 is developing CMP-002 for SYNGAP1-related disorders, a genetic haploinsufficiency CNS disorder with no approved treatments. This program aims to be the first disease-modifying therapy for SYNGAP patients, with tens of thousands affected globally [2][3][34]. 2. **Platform Technology**: The company utilizes a proprietary WRAP platform to identify and drug regulatory RNAs, allowing for selective increases in protein expression. This platform is designed to address various haploinsufficient diseases, including developmental epileptic encephalopathies (DEEs) [4][5][6]. 3. **Preclinical Data**: Strong preclinical data supports the efficacy of CMP-002, showing potential for significant disease modification. The program is currently completing GLP-tox studies, with plans to enter clinical trials later in the year [3][8][27]. 4. **Market Opportunity**: Camp4 estimates at least 20,000 patients in the U.S. and EU5 with SYNGAP1, with only about 25% diagnosed. Increased awareness and diagnostic capabilities are expected to drive this number higher [15][17]. 5. **Collaborations**: The company has formed a partnership with GSK to explore additional targets in CNS and kidney diseases, providing non-dilutive capital and expanding the application of its platform [9][60][61]. Important but Overlooked Content 1. **Patient-Centric Approach**: The presentation emphasized the impact of SYNGAP1 on patients and their families, highlighting the emotional and physical challenges faced by caregivers [10][11][12]. 2. **Regulatory Strategy**: Camp4 is engaging with regulatory agencies to facilitate a smooth transition into clinical trials, with a focus on rapid enrollment and diverse endpoints to demonstrate efficacy [28][30][50]. 3. **Financial Stability**: The company is funded through the end of 2027, with additional financing available upon achieving regulatory milestones, ensuring a stable runway for development [61]. Future Directions - **Clinical Trials**: Plans to initiate a global phase one-two study for CMP-002, focusing on various endpoints including seizures, sleep, motor function, and cognitive development [28][29][30]. - **Expansion of Pipeline**: Camp4 aims to leverage its platform to develop additional programs targeting other haploinsufficient diseases, with expectations to announce new initiatives later in the year [34]. - **Long-Term Vision**: The company aspires to become a leader in the field, drawing parallels to successful companies like Alnylam, while maintaining a strong focus on patient needs and innovative therapies [34].

Core Viewpoint - CAMP4 Therapeutics Corporation (CAMP) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Revisions - The Zacks rating system is based on the changing earnings picture of a company, specifically tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - Recent trends show that analysts have been raising their earnings estimates for CAMP4 Therapeutics, with a 0.2% increase in the Zacks Consensus Estimate over the past three months [9]. Impact on Stock Prices - Changes in earnings estimates are strongly correlated with near-term stock price movements, largely due to institutional investors who adjust their valuations based on these estimates [5]. - The upgrade to Zacks Rank 2 places CAMP4 Therapeutics in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [11]. Investment Implications - Rising earnings estimates and the corresponding rating upgrade imply an improvement in CAMP4 Therapeutics' underlying business, which could lead to increased buying pressure and a higher stock price [6][4]. - The Zacks Rank system has a proven track record, with Zacks Rank 1 stocks averaging an annual return of +25% since 1988, highlighting the effectiveness of tracking earnings estimate revisions for investment decisions [8][7].

Core Viewpoint - CAMP4 Therapeutics is a clinical-stage biopharmaceutical company focused on developing RNA-targeting therapeutics aimed at treating genetic diseases by restoring healthy protein levels [1][3]. Group 1: Corporate Update - Josh Mandel-Brehm, President & CEO of CAMP4, will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 3:45 p.m. PST [1]. - The presentation will be available via webcast on CAMP4's investor relations page, with a replay accessible for 30 days post-conference [2]. Group 2: Company Overview - CAMP4 is developing disease-modifying treatments for over 1,200 genetic diseases where increasing healthy protein levels may provide therapeutic benefits [3]. - The company's approach involves amplifying mRNA by targeting regulatory RNAs (regRNAs), which are crucial for gene expression control [3]. - CAMP4's proprietary RAP Platform facilitates the mapping of regRNAs and the creation of therapeutic candidates aimed at addressing haploinsufficient and recessive partial loss-of-function disorders [3].

Core Viewpoint - CAMP4 Therapeutics Corporation has announced the pricing of its underwritten offering of 5,000,000 shares of common stock at $6.00 per share, aiming to raise gross proceeds of $30.0 million to support its product development and general corporate purposes [1][2]. Group 1: Offering Details - The offering is expected to close on or about December 19, 2025, pending customary closing conditions [2]. - All securities in the offering are being sold by the Company, with participation from both new and existing investors, including notable firms like Janus Henderson Investors and EcoR1 Capital [3]. - Leerink Partners is acting as the sole underwriter for the offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering, along with existing cash and marketable securities, will primarily be used to support continued development activities for the Company's product candidates and for general corporate purposes [2]. Group 3: Company Overview - CAMP4 Therapeutics is focused on developing regulatory RNA-targeting therapeutics aimed at upregulating gene expression to treat a variety of genetic diseases [6]. - The Company utilizes its proprietary RAP Platform® to map regulatory RNAs and create therapeutic candidates targeting genes associated with over 1,200 disorders, where a modest increase in protein expression could be clinically significant [6].

Core Insights - CAMP4 Therapeutics has entered a strategic collaboration with GSK to develop antisense oligonucleotide (ASO) drug candidates targeting neurodegenerative and kidney diseases, leveraging CAMP4's RAP Platform [1][4][5] Financial Terms - CAMP4 will receive an upfront payment of $17.5 million and is eligible for additional milestone-based payments and tiered royalties on future product sales [3][1] Collaboration Details - The collaboration aims to identify and develop ASO candidates that increase the expression of validated genetic targets, addressing the critical role of protein under-expression in diseases [2][5] - GSK will handle the further development and commercialization of the ASO drug candidates identified through this partnership [4] Technology and Approach - CAMP4's RAP Platform is designed to identify regulatory RNAs (regRNAs) that control gene expression, enabling the generation of ASO candidates that amplify target gene expression [4][6] - The company focuses on amplifying mRNA to develop disease-modifying treatments for over 1,200 genetic diseases where increased protein expression may provide therapeutic benefits [6]

Core Insights - CalAmp has achieved the Caterpillar Supplier Excellence Certification for 2025, marking the second consecutive year of receiving this recognition, which highlights the company's adherence to high standards in quality, on-time delivery, service, and manufacturing discipline [2][3]. Supplier Performance - The Caterpillar Supplier Excellence Recognition program identifies top-performing suppliers that consistently excel in quality, delivery, service, capacity planning, and compliance, placing CalAmp among the elite suppliers in Caterpillar's global supply chain [3]. - Over the past year, CalAmp recorded a defect rate of 51 defects per million incoming parts, translating to approximately 0.005 percent, or one defect in every 20,000 parts shipped, showcasing the company's commitment to quality [5]. Manufacturing Standards - CalAmp has implemented an Automotive Quality Management System aligned with IATF 16949 principles to meet the rigorous requirements of automotive OEMs, ensuring that each device is designed and manufactured to high standards [7]. - The company emphasizes early planning and feasibility reviews before production, defined manufacturing and testing processes, extensive reliability and environmental testing, and strict governance over design and component changes to ensure long-term product stability [11]. Commitment to Innovation - As OEMs evolve their connected equipment strategies, CalAmp focuses on delivering robust, reliable, and secure telematics solutions, supporting various industries such as construction, mining, agriculture, and on-road equipment [8]. - The company has over 10 million active edge devices and holds more than 220 approved or pending patents, positioning itself as a leader in telematics innovation and dependability [9].